Cohance Lifesciences has informed that the United States Food and Drug Administration (USFDA) inspected the Company’s API manufacturing facility at Jaggaiahpet, Andhra Pradesh, India (FEI No. 3005554260), from 14 September to 19 September 2026. The inspection concluded with the issuance of a Form FDA 483 containing five observations. The Company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline. The Company remains committed to quality and regulatory compliance.
The above information is a part of company’s filings submitted to BSE.
